久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Reaching for top echelon in R&D of new drugs

By ZHOU WENTING in Shanghai | China Daily | Updated: 2021-11-02 09:22
Share
Share - WeChat
A booth of Boehringer-Ingelheim during the 2020 CIIE in Shanghai. [Photo/CHINA DAILY]

China is expected to enter the world's top echelon in the research and development of new drugs within the next decade as many local biomedical companies have cultivated a strong R&D prowess and are thriving in clinical trials, said industry experts.

Such robust development momentum, which has been on the rise over the past five years, is also a result of deepened collaborations with multinational pharmaceutical giants. The country's ecosystem also encourages vibrant innovations under the Health China 2030 Initiative, they said.

Innovation vitality from home and abroad can be propelled mutually and form positive interaction cycles to provide a steady stream of new drugs, said some multinational biotech companies ahead of the fourth China International Import Expo, which will open this week. Since its launch in 2018, the CIIE has evolved into a platform for the world's leading corporations as well as emerging companies to exhibit the latest innovations and step up collaborations with local partners.

The prosperity and enthusiasm of new drug development in China is not seen elsewhere today, said Wang Bin, general manager of Boehringer Ingelheim Biopharma China.

"The speed of innovative and new therapies applying for clinical trials and approved for the market in China each year is outpacing others and has been showing an impressive straight uptrend for years," said Wang.

"And in the next generation of therapies-gene- and cell-related fields-the gap between China and the leading players is smaller than in traditional drugs, thanks to China's quick acceptance of new things and diligence," he said.

The country's health ecosystem to support innovative therapies is a major booster, Wang said. The number of expensive biomedicines included in the national medical reimbursement plan has been rising each year, which created a virtuous circle between making investments and seeing the hope of strong returns on those investments.

The country has also allowed the Contract Development Manufacturing Organization-or CDMO model-to help research-oriented companies focus on R&D while outsourcing drug development and manufacturing. It also lets outsourced providers commercialize products.

"Such supportive policies plus large market need, including the aging trend, have attracted a large number of talented professionals and experts, ranging from young graduates to veterans in pharmaceutical enterprises overseas, to return and their entrepreneurial projects have begun to produce positive results," Wang said.

China is already in the world's second echelon of new drug R&D based on the quantity of the innovative product pipelines. "The divide between it and the first echelon, the United States, is narrowing," said Chen Kaixian, an academic who specializes in new drug research at the Chinese Academy of Sciences.

Citing data between 2017 and 2020, a McKinsey report showed that the ratio of locally developed innovative drugs approved in China leaped from 2 percent to 37 percent, although multinational businesses also accelerated the speed of introducing innovative therapies in the country.

"It's a golden time for China's biomedical R&D and innovations. We can definitely stand at the forefront of the world's biomedical innovation with capital assistance after accumulations and summarizations," said Niu Xiaofeng, R&D director of Elpiscience, a Shanghai-based clinical-stage biopharmaceutical company focusing on cancer immunotherapy.

Elpiscience was among 340 biomedical enterprises competing in the national finals of biotechnology during the China Innovation and Entrepreneurship Competition in October.

The company's more than 10 innovative molecules in discovery, with focus on innate immunity and tumor microenvironment, competed with an innovative antibody drug treating tumors. The company said the project has entered the process development stage and is expected to launch Phase-I clinical trials in 2023.

The vitality of new drug R&D with a richer pipeline in China is closely related to the business environment increasingly conducive to innovations and there exist mutual promotions between the R&D dedications and results from local and international investments, said executives of enterprises from home and abroad.

Dan Brindle, president of Novartis Group (China), said the company has had a strong flow of new drug approvals and therapies or indications included in the national reimbursement drug list to expand patients' accessibility to drugs over the past years.

"We expect that China will become our second-largest market in the near future," said Brindle. "I have to give credit to the foresight of the Chinese government and policymakers who continue to evolve the ecosystem in support of innovation in life sciences."

Brindle cited the example of Entrestro, a Novatis drug launched in China in 2017 to treat heart failure and approved for the new indication of essential hypertension in June.

"China was the world's second market to have the hypertension indication for this therapy. It demonstrated the tremendous progress being made on the regulatory front in the country," he said.

He said that within five years, the company plans to submit 50 new drug applications in China, and aims to achieve simultaneous submissions in China and elsewhere for more than 90 percent of new drugs by 2024.

During the CIIE, Novartis will display some cutting-edge therapies not yet marketed in China, including a first-in-class small interfering RNA-ribonucleic acid-cholesterol-lowering treatment with only two doses a year.

Following the 2019 investment of an additional 863 million yuan ($135 million) to upgrade a Shanghai-based R&D facility, the Roche Innovation Center Shanghai, Roche announced Roche Accelerator, an operation to help accelerate healthcare innovation in China, in May and will demonstrate it during the fourth CIIE.

"As Roche's first in-house accelerator globally, the project will help accelerate the development of healthcare innovation in China and empower the local medical innovation ecosystem," said Vivian Bian, CEO of Roche Pharmaceuticals China.

Startups in the Shanghai-based accelerator with an investment of nearly 300 million yuan each will have access to Roche's full spectrum of local resources ranging from early research and development to commercialization, and will also be provided with research funding support or subsidies.

The company said that scientists from the Roche Innovation Center Shanghai and Roche Group's global R&D centers will engage with entrepreneurs and share their insights.

Also, the accelerator will join hands with strategic partners, including Zhangjiang Group, to foster a batch of startups that will play a leading role in the global innovation ecosystem.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲影院手机版777点击进入影院 | 午夜啪啪福利视频 | 情侣自拍啪啪 | 97免费在线| 国产成人女人视频在线观看 | 成人中文在线 | 深夜国产 | 欧美特级一级毛片 | 深夜爽爽爽福利动态图 | 国产黄色大片网站 | 久久777国产线看是看精品 | 国产精品久久久久久久福利院 | 久久国产精品免费观看 | 久久久国产99久久国产首页 | 国产自在自线午夜精品视频在 | 日本aaaa精品免费视频 | 成人毛片1024你懂的 | 曰本美女高清在线观看免费 | 精品免费国产一区二区三区 | 最新亚洲精品国自产在线观看 | 成人精品久久 | 国产成人精品曰本亚洲77美色 | 免费a级毛片无码 | 波多野结衣被强在线视频 | 国模在线播放 | 深夜福利视频大全在线观看 | 欧美精品 日韩 | 日本三级网站在线线观看 | 在线国产一区二区三区 | 精品日韩一区二区三区视频 | 看片亚洲 | 国产一级毛片夜一级毛片 | a级片免费观看 | 国产成人自拍在线 | 成年人在线视频免费观看 | 999国产精品亚洲77777 | 欧美午夜伦y4480私人影院 | 亚洲国产精品一区二区第四页 | 久色视频在线 | 神马我我不卡伦影视 | 国产tv在线 |